Serum Level of Macrophage Migration Inhibitory Factor as a Useful Parameter of Clinical Course in Patients with Wegener's Granulomatosis and Relapsing Polychondritis
Restricted accessResearch articleFirst published online November, 2001
Serum Level of Macrophage Migration Inhibitory Factor as a Useful Parameter of Clinical Course in Patients with Wegener's Granulomatosis and Relapsing Polychondritis
Novel biological activities of macrophage migration inhibitory factor (MIF) have been rediscovered. In addition, elevation of the serum MIF level has been reported in different types of disorders, including various inflammatory and autoimmune diseases. In the present study, serum MIF levels were analyzed in patients with Wegener's granulomatosis (WG) and relapsing polychondritis. It was shown that the serum MIF levels in these patients were significantly higher than those of normal healthy controls. In a WG patient, the MIF level showed a good correlation with clinical symptoms and C-ANCA titers. Thus, serum MIF levels will be a useful laboratory parameter for following the clinical course of WG patients and determining medical treatment. The immunopathologic roles of MIF in these diseases are discussed.
BloomBRBennettB. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science1966; 153: 80–2.
2.
NishihiraJ. Reevaluation of the biological functions of macrophage migration inhibitory factor (MIF) within and beyond the immune system. Recent Res Dev Immunol1999; 1: 95–111.
3.
NishihiraJ. Novel pathophysiological aspects of macrophage migration inhibitory factor. Int J Mol Med1998; 2: 17–28.
4.
KitaichiNKotakeSSasamotoY. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci1999; 40: 247–50.
5.
MikulowskaAMetzCNBucalaRHolmdahlR. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol1997; 158: 5514–7.
6.
GodmanGCChurgJ. Wegener's granulomatosis. Pathology and review of the literature. AMA Arch Pathol1954;58:533–53.
7.
CarringtonCBLiebowA. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med1966; 41: 497–527.
8.
van der WoudeFJRasmussenNLobattoS. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet1985; 1: 425–9.
9.
MichetCJJrMcKennaCHLuthraHSO'FallonWM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med1986; 104: 74–8.
10.
TeratoKShimozuruYKatayamaK. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum1990; 33: 1493–500.
11.
TrenthamDE. Polychondritis. In: RichRRClinical immunology: principles and practice. St Louis, Mo: Mosby, 1996: 1395–400.
12.
DamianiJMLevineHL. Relapsing polychondritis — report often cases. Laryngoscope1979; 89: 929–46.
13.
NishihiraJKoyamaYMizueY. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharides. Cytokine1998; 10: 199–205.
14.
CalandraTBernhagenJMetzCN. MIF as a glucocorticoid-induced modulator of cytokine production. Nature1995; 377: 68–71.
15.
HoffmanGS. Testing with antineutrophil cytoplasmic antibody to diagnose Wegener granulomatosis. Ann Intern Med1996; 125: 622–3.
16.
CsernokEMüllerAGrossWL. Immunopathology of ANCA-associated vasculitis. Intern Med1999; 38: 759–65.
17.
MascherBSchmittWCsernokE. Polymorphisms in the tumor necrosis factor genes in Wegener's granulomatosis. Exp Clin Immunogenet1997; 14: 226–33.
18.
BernhagenJBacherMCalandraT. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med1996; 183: 277–82.
19.
CockwellPBrooksCJAduDSavageCOS. Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int1999; 55: 852–63.
20.
SchmittWHHeesenCCsernokERautmannAGrossWL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Arthritis Rheum1992; 35: 1088–96.
21.
BoehmeMWJSchmittWHYouinouPStremmelWRGrossWL. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med1996; 101: 387–94.
22.
OnoderaSTanjiHSuzukiK. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine1999; 11: 163–7.
23.
KochAEKunkelSLHarlowLA. Enhanced production of monocyte chemoattractant protein–1 in rheumatoid arthritis. J Clin Invest1992; 90: 722–99.
24.
CalandraTBernhagenJMitchellRABucalaR. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med1994; 179: 1895–902.
25.
KitaichiNMatsudaAKotakeS. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies. Curr Eye Res2000; 20: 109–14.
26.
CalandraTEchtenacherBRoyDL. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med2000; 6: 164–70.
